Albert Khouri, MD
Ophthalmology · Newark, NJNPI 1093915837
Payments from drug & device makers
Across 501 payments — averaging $1081.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$246K
- Bausch & Lomb Americas Inc.$98K
- Glaukos Corporation$56K
- Aerie Pharmaceuticals, Inc.$53K
- Optovue, Inc.$45K
- Alcon$29K
- plus $15K from 9 others
What the payments were for
- Consulting fees$52,03012%
- Speaking & faculty fees$344,37181%
- Travel & lodging$18,2874%
- Food & beverage$12,6763%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 266 | $245,663 |
| Bausch & Lomb Americas Inc. | 90 | $97,513 |
| Glaukos Corporation | 43 | $55,944 |
| Aerie Pharmaceuticals, Inc. | 39 | $53,494 |
| Optovue, Inc. | 1 | $45,000 |
| Alcon | 29 | $29,094 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $12,101 |
| NEW World Medical,inc. | 5 | $1,216 |
| Sight Sciences, Inc. | 7 | $654 |
| Iridex Corporation | 1 | $500 |
| Tarsus Pharmaceuticals, Inc. | 1 | $122 |
| Dompe US, Inc. | 1 | $122 |
| Amgen | 1 | $120 |
| Biotissue Holdings Inc. | 1 | $33 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$107,835
- Rocklatan$79,908
- DURYSTA$79,673
- Rhopressa$68,232
- LUMIGAN$46,477
- XR$45,000
- iStent inject Trabecular Micro-Bypass Stent System$23,372
- COMBIGAN$19,956
- iDose$11,204
- SIMBRINZA$9,765
- Travoprost Intraocular Implant - iDose$4,950
- ALPHAGAN P$3,175
- iStent Trabecular Micro-Bypass Stent System$3,000
- iDose TR$2,400
- iStent infinite Trabecular Micro-Bypass System Model iS3$2,400
- iStent inject W$2,250
- OMNI(R) SURGICAL SYSTEM (US)$539
- SION SURGICAL INSTRUMENT$427
- RESTASIS$400
- iDoseTR$192
How this compares
$541,591 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 547 | $282,324 |
| VyzultaLatanoprostene Bunod | 238 | $106,623 |
| RocklatanNetarsudil Mesylat/Latanoprost | 222 | $102,241 |
| RhopressaNetarsudil Mesylate | 171 | $87,114 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 237 | $72,461 |
| Alphagan PBrimonidine Tartrate | 164 | $71,675 |
| RestasisCyclosporine | 75 | $68,219 |
| CombiganBrimonidine Tartrate/Timolol | 139 | $63,211 |
| Brimonidine Tartrate | 689 | $51,914 |
| Methazolamide | 103 | $36,186 |
| XiidraLifitegrast | 19 | $18,442 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 85 | $16,047 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 974 | $15,611 |
| Brinzolamide | 72 | $15,332 |
| Travoprost | 100 | $14,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $245,663 | $485,429925 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $53,494 | $189,355393 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $97,513 | $125,065257 claims |
| AlconSimbrinza, Azopt | $29,094 | $82,898260 claims |
| NovartisTravatan Z | $15 | $8,39916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Newark
- Robert FechtnerNewark$324K
- Marco ZarbinNewark$52K
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.